{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:23:20Z","timestamp":1770290600469,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K16078"],"award-info":[{"award-number":["21K16078"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005072","name":"Japanese Circulation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cjco.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:47:07Z","timestamp":1678276027000},"page":"380-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"5","author":[{"given":"Kazuki","family":"Kagami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-0688","authenticated-orcid":false,"given":"Masaru","family":"Obokata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayami","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Sorimachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2023.03.001_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cardfail.2020.08.008","article-title":"Characterization of the progression from ambulatory to hospitalized heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.amjmed.2019.06.040","article-title":"Prior heart failure hospitalization and outcomes in patients with heart failure with preserved and reduced ejection fraction","volume":"133","author":"Malik","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.cjco.2023.03.001_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.03.001_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.echo.2016.10.016","article-title":"The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"30","author":"Lancellotti","year":"2017","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjco.2023.03.001_bib8","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2023.03.001_bib9","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.03.001_bib10","first-page":"87","article-title":"Exercise stress echocardiography in the diagnostic evaluation of heart failure with preserved ejection fraction","volume":"9","author":"Harada","year":"2022","journal-title":"J\u00a0Cardiovasc Dev Dis"},{"key":"10.1016\/j.cjco.2023.03.001_bib11","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.03.001_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.03.001_bib13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.03.001_bib14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.03.001_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.03.001_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cjco.2023.03.001_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2023.03.001_bib19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u201cOMics\u201d in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.03.001_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jcmg.2017.10.007","article-title":"Association of active and passive components of LV diastolic filling with exercise intolerance in heart failure with preserved ejection fraction: mechanistic insights from spironolactone response","volume":"12","author":"Kosmala","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2023.03.001_bib21","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.03.001_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT Trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2016.06.190","article-title":"Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients","volume":"220","author":"Gu","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ejhf.2122","article-title":"A\u00a0prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF","volume":"23","author":"Sugumar","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2023.03.001_bib26","first-page":"1297","article-title":"Association between lung ultrasound B-lines and exercise-induced pulmonary hypertension in patients with connective tissue disease","volume":"38","author":"Kagami","year":"2021","journal-title":"Echocardiography"},{"key":"10.1016\/j.cjco.2023.03.001_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41598-021-03974-6","article-title":"The H2FPEF and HFA-PEFF algorithms for predicting exercise intolerance and abnormal hemodynamics in heart failure with preserved ejection fraction","volume":"12","author":"Amanai","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2023.03.001_bib28","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","article-title":"Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction","volume":"39","author":"Obokata","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.03.001_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cardfail.2021.04.014","article-title":"Salutary acute effects of exercise on central hemodynamics in heart failure with preserved ejection fraction","volume":"27","author":"Obokata","year":"2021","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib30","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacc.2018.11.033","article-title":"Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review","volume":"73","author":"McHugh","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.03.001_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014967","article-title":"Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"98","author":"Xiang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjco.2023.03.001_bib33","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2023.03.001_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A\u00a0randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2023.03.001_bib35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.03.001_bib36","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.03.001_bib37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.03.001_bib40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.03.001_bib41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2023.03.001_bib42","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.echo.2019.06.017","article-title":"Myocardial strain for identification of \u03b2-blocker responders in heart failure with preserved ejection fraction","volume":"32","author":"Park","year":"2019","journal-title":"J\u00a0Am Soc Echocardiogr"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:10:15Z","timestamp":1762902615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X23000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2589790X23000550"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2023.03.001","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}